Isomorphic Labs 正在談判約 5B 美元融資，估值約 50B，其首款藥物設計引擎基於 AlphaFold 3。
- 技術亮點：引擎可預測蛋白質折疊與藥物分子結合，允許化學家在電腦上先篩選分子，減少實驗成本。
AI 伴隨問答
針對這篇報導有疑問？可直接點選快捷問題或向 AI 追問背景脈絡與技術細節：
Bloomberg: Isomorphic Labs, The Alphabet company spun out of Google DeepMind is negotiating a roughly $5B raise at about $50B, with no drug yet tested in people.
Their product is a drug-design engine built on AlphaFold 3. It predicts how proteins in the body fold and how a candidate drug molecule will latch onto them.
Chemists normally find this out through slow, expensive lab trial and error, so the engine lets them design and rank molecules on a computer first and only make the promising ones.
If software predicts how a candidate molecule binds its protein target, chemists can drop weak designs before paying for synthesis and animal studies.
Without human data, a $50B price rests on prediction accuracy and pharma partnerships, not evidence that its molecules work in patients.